Emerging Markets

November 2013

Non-Small-Cell Lung Cancer in Argentina, Brazil, and Mexico

Report Authors
Natalia Reoutova, M.A., M.Sc.
Lade Ayodele, M.B.B.S., M.P.H.
  • Pages:113
  • Tables:32
  • Figures:71
  • Citations:N/A
  • Drugs:20
  • Interviews:20 interviews; 70 surveys

Introduction:

The combined NSCLC market of Argentina, Brazil, and Mexico will grow at a rate of 6% per year between 2013 and 2018, and the number of NSCLC incident cases will increase by 25% between 2013 and 2023. Growing NSCLC population, changes in medical practice and reimbursement and the resulting continued uptake of targeted therapies, and entry of eleven new high-value branded agents are the key factors driving this market. In this report, we examine the trends within the NSCLC pharmaceutical markets of Argentina, Brazil, and Mexico, which are characterized by government-sponsored healthcare systems that have a wide population reach but impose limitations in terms of cancer drug coverage; growing uptake of biomarker-specific agents, in particular, EGFR inhibitors; and growing drug-treatable populations.

Questions Answered in This Report:

  *   The combined NSCLC market of Argentina, Brazil, and Mexico will grow at a rate of 6% per year between 2013 and 2018. What is the size of the market in each country? Can we expect faster growth in some markets over others? What factors will drive growth in this market? What factors will constrain it?

  *   Between 2013 and 2018, eleven new therapies for the treatment of NSCLC are expected to enter Argentina, Brazil, and Mexico. How widely will these agents be used, and will they pose considerable competition to the current therapies? Will these agents be from existing drug classes, or will they feature novel mechanisms of action?

  *   The combined number of incident cases of NSCLC in Argentina, Brazil, and Mexico will increase by 25% between 2013 and 2023. How big were the individual country-specific populations in 2013? Will some populations grow at a faster pace? What are the factors determining this growth? Do stage distributions and drug-treatment rates differ significantly between the three countries? How do they compare to the major markets?

  *   Pricing of therapies and reimbursement policies in the public sector are major factors influencing expenditure on NSCLC treatments in Argentina, Brazil, and Mexico. Which social programs and national institutions provide coverage for the treatment of NSCLC in Argentina, Brazil, and Mexico? Is coverage expected to improve in the near future? How does the pricing of branded and generic NSCLC agents differ between Argentina, Brazil, Mexico, and the major markets?

Scope:

Primary research: 70 oncologists surveyed across Argentina. Separate in-depth interviews with 8 Argentine oncologists, 6 Brazilian oncologists, and 6 Mexican oncologists.

Epidemiology: Total incident cases of NSCLC in Argentina, Brazil, and Mexico over a ten-year period (2013-2023) by age, stage, histology, and gender.

Current therapies and medical practice: Reporting use of brands and generics for the NSCLC treatments available in Argentina, Brazil, and Mexico.

Pricing and reimbursement: Prices of NSCLC therapies in Argentina, Brazil, and Mexico versus other major markets and analysis of the impact of government reimbursement on treatment trends.

Market forecast features: Our analysis evaluates rates of NSCLC progression and rates of drug treatment with NSCLC therapies, across all stages of the disease. We include a forecast of current and emerging therapies within platinum agents, antitubulins, antimetabolites, other cytotoxic agents, angiogenesis inhibitors, EGFR inhibitors, ALK inhibitors, immunotherapies, and c-Met inhibitors from 2013 through 2018, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.


Search Reports

Mentioned in this report:

  • - AstraZeneca
  • - Boehringer Ingelheim
  • - Bristol-Myers Squibb
  • - Celgene
  • - Eisai
  • - Eli Lilly
  • - Genentech
  • - Merck & Co
  • - Novartis
  • - Pfizer
  • - Pierre Fabre
  • - Roche
  • - Sanofi
Decision Resources Group brands include: